About SeylanMED
SeylanMED is a Healthcare company based in Berkeley (United States) founded in 2016, and was acquired by DermBiont in October 2020. Treatments for skin disorders are developed by the company. The company was acqui-hired. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its competitors include Revance Therapeutics, Castle Creek Pharma and Dermavant; 3 of its 3 listed competitors have raised funding.
Company details
SeylanMED was founded in 2016 and is based in Berkeley, United States. Operations are centered in the biotechnology sector, where treatments for skin disorders are developed. A lead drug candidate, a topical small molecule AKT inhibitor gel, is being advanced for potential use in treating seborrheic keratosis. The companys domain is seylanmed.com, supporting its research and development activities.
- Headquarters Berkeley, United States
- Stage Acquired
- SectorsHealthcare
- Website seylanmed.com
- Acquired by DermBiont (Oct 2020)
Investors in SeylanMED
SeylanMED has secured backing from 1 investor. Prominent investors backing the company include DermBiont.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Microbial therapeutics for skin diseases are developed. | 2015 | dermbiont.com | Melrose, United States |
Investor details for SeylanMED
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SeylanMED
12 people are tracked at SeylanMED (9 in leadership, 2 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Emma Taylor | Chief Medical Officer | Leadership |
Sanjay Jain | Chief Development Officer | Leadership |
Karl Beutner | CEO & Co-Founder | Leadership |
Nichola Eliovits | Chief Business Officer & Co-Founder | Leadership |
Max N. Dawson | COO | Leadership |
Ravi Pandrapragada | Senior Vice President Of Development | Leadership |
Christine Coticchia | Director, Translational Research And Assay Development | Leadership |
Max Dawson | Chief Operating Officer | Leadership |
Ramesh Putheti | Director-cmc Analytical Development And Quality Control | Leadership |
Wilder Ramsey | Director | Board & advisors |
Steven Basta | Director | Board & advisors |
Esther Miller | Senior Scientist | Team |
Complete people profiles for SeylanMED
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SeylanMED
2 dated milestones of SeylanMED across 4 years, from founding to its latest funding, stage changes and deals.
- Founded SeylanMED is founded.
- Exit Acquired by DermBiont.
Competitors of SeylanMED
SeylanMED has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Castle Creek Pharma and Dermavant.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| dermavant.com | 2016 | Phoenix, United States | $160M | Small molecule therapeutics for inflammatory skin diseases are developed. |
Detailed competitors of SeylanMED
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as SeylanMED (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Seylanmed
Complete news archive for SeylanMED
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SeylanMED
SeylanMED was founded in 2016.
SeylanMED is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
SeylanMED was founded in 2016 and is based in Berkeley, United States. Operations are centered in the biotechnology sector, where treatments for skin disorders are developed. A lead drug candidate, a topical small molecule AKT inhibitor gel, is being advanced for potential use in treating seborrheic keratosis. The companys domain is seylanmed.com, supporting its research and development activities.
SeylanMED's top competitors include Revance Therapeutics, Dermavant and Castle Creek Pharma.
SeylanMED has 1 investor. Key investors include DermBiont.
Yes. SeylanMED was acquired by DermBiont in October 2020.